We are excited to inform that SFL was acquired by Veristat, combining the strengths of two organizations with a shared commitment to quality and scientific integrity. SFL chose to join Veristat to capitalize on our common abilities to solve complex drug and medical product challenges with scientific-minded thinking to support our clients’ ongoing and future needs.

The combination of our teams further supports our ability to positively influence the scientific progress, regulatory assessment and launch success of treatments for patients with difficult-to-treat diseases and conditions. Veristat brings more than 27 years’ experience in clinical trial planning and execution, with deep expertise in novel therapeutics. They offer bold thinking and a comprehensive range of services to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval and commercialization.

Veristat expands SFL’s ability to work closely with the FDA and provides a more substantial range of clinical development services such as global clinical operations, biostatistics and programming, medical affairs, and extended regulatory and medical writing support.

SFL’s founder and CEO, Shayesteh Fürst-Ladani, will continue her role as Head of the SFL Group and play a leadership role within Veristat, available to support our clients’ program and business needs.

See here the press release about the combination of SFL and Veristat.